AR125118A1 - Actividad antiviral de inhibidores de vps34 - Google Patents
Actividad antiviral de inhibidores de vps34Info
- Publication number
- AR125118A1 AR125118A1 ARP210103254A ARP210103254A AR125118A1 AR 125118 A1 AR125118 A1 AR 125118A1 AR P210103254 A ARP210103254 A AR P210103254A AR P210103254 A ARP210103254 A AR P210103254A AR 125118 A1 AR125118 A1 AR 125118A1
- Authority
- AR
- Argentina
- Prior art keywords
- group
- heteroaryl
- aryl
- c3alkyl
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Métodos de tratamiento de infecciones virales, tales como infecciones por coronavirus, en pacientes que lo necesitan, que comprenden administrar a dichos pacientes un inhibidor de VPS34. Reivindicación 1: Un método para paliar o tratar una infección viral en un paciente que lo necesite, caracterizado porque comprende administrar al paciente una cantidad terapéuticamente eficaz de un compuesto representado por la fórmula (1) o una sal farmacéuticamente aceptable, estereoisómero, o tautómero del mismo, donde: R¹ se selecciona entre el grupo que consiste en arilo y heteroarilo, donde dicho arilo y dicho heteroarilo son monocíclicos o bicíclicos y cada arilo y heteroarilo está opcionalmente sustituido con una o más instancias independientes de un sustituyente seleccionado entre el grupo que consiste en R⁵, R⁶, R⁷ y R⁸; cada R², R³, R⁴ se selecciona en forma independiente entre el grupo que consiste en H, C₁-C₃haloalquilo, y C₁-C₃alquilo; cada R⁵, R⁶, R⁷, y R⁸ se selecciona en forma independiente entre el grupo que consiste en halógeno, C₁-C₆alquilo, C₁-C₆alcoxi, C₁-C₆haloalquilo, amino, -NHSO₂R⁹, hidroxi, fenilo, y un heteroarilo monocíclico; y R⁹ se selecciona entre C₁-C₃haloalquilo y C₁-C₃alquilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063118512P | 2020-11-25 | 2020-11-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR125118A1 true AR125118A1 (es) | 2023-06-14 |
Family
ID=81206898
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103254A AR125118A1 (es) | 2020-11-25 | 2021-11-25 | Actividad antiviral de inhibidores de vps34 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220184092A1 (es) |
| EP (1) | EP4251167A1 (es) |
| JP (1) | JP2023550640A (es) |
| CN (1) | CN117136062A (es) |
| AR (1) | AR125118A1 (es) |
| CA (1) | CA3200003A1 (es) |
| TW (1) | TW202237131A (es) |
| WO (1) | WO2022115549A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL302807A (en) | 2020-11-18 | 2023-07-01 | Deciphera Pharmaceuticals Llc | GCN2 and PERK kinase inhibitors and methods of using them |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077113B2 (en) * | 2016-02-19 | 2021-08-03 | Sprint Bioscience Ab | 6-aryl-4-morpholin-1-ylpyridone compounds useful for the treatment of cancer and diabetes |
| EP4181929A2 (en) * | 2020-07-14 | 2023-05-24 | Georgia State University Research Foundation Inc. | Methods for screening novel coronavirus antivirals and methods of using antivirals for the treatment of coronavirus infections |
-
2021
- 2021-11-24 EP EP21856943.2A patent/EP4251167A1/en active Pending
- 2021-11-24 JP JP2023531513A patent/JP2023550640A/ja active Pending
- 2021-11-24 CN CN202180089892.5A patent/CN117136062A/zh active Pending
- 2021-11-24 WO PCT/US2021/060747 patent/WO2022115549A1/en active Application Filing
- 2021-11-24 US US17/534,762 patent/US20220184092A1/en not_active Abandoned
- 2021-11-24 CA CA3200003A patent/CA3200003A1/en active Pending
- 2021-11-25 AR ARP210103254A patent/AR125118A1/es unknown
- 2021-11-25 TW TW110143952A patent/TW202237131A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022115549A1 (en) | 2022-06-02 |
| CA3200003A1 (en) | 2022-06-02 |
| CN117136062A (zh) | 2023-11-28 |
| EP4251167A1 (en) | 2023-10-04 |
| US20220184092A1 (en) | 2022-06-16 |
| TW202237131A (zh) | 2022-10-01 |
| JP2023550640A (ja) | 2023-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| PE20221339A1 (es) | Inhibidores de parp1 | |
| PE20230238A1 (es) | Inhibidores de kras g12c | |
| DOP2018000187A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| PE20180232A1 (es) | Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue | |
| BR112022000064A2 (pt) | Inibidores de hpk1 e usos dos mesmos | |
| CL2020000860A1 (es) | Compuestos monobactámicos cromanos para el tratamiento de infecciones bacterianas. | |
| AR111314A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR116283A1 (es) | Inhibidores del sarcómero cardíaco | |
| AR116115A1 (es) | Dimetil amino azetidina amidas como inhibidores de jak | |
| EA201991894A1 (ru) | ПИПЕРИДИН-ЗАМЕЩЕННЫЕ ИНГИБИТОРЫ Mnk И СВЯЗАННЫЕ С НИМИ СПОСОБЫ | |
| MD3902803T2 (ro) | Inhibitori aza-heterobiciclici ai MAT2A și metode de utilizare pentru tratarea cancerului | |
| AR125118A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| AR119614A1 (es) | Formas en estado sólido de (s)-2-(((s)-6,8-diflúor-1,2,3,4-tetrahidronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2-il)-1h-imidazol-4-il)pentanamida y usos de la misma | |
| DOP2023000060A (es) | Inhibidores de la línea-1 para tratar enfermedades antecedentes de la invención | |
| PE20230180A1 (es) | Uso de bi853520 en tratamiento contra el cancer | |
| ECSP23095674A (es) | Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn) | |
| AR114082A1 (es) | INHIBIDORES DE LA PI4KIIIb | |
| AR125122A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| AR125117A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| AR125120A1 (es) | Actividad antiviral de inhibidores de vps34 | |
| CO2023013321A2 (es) | Compuestos de oxoisoindolina sustituidos con piridinilo | |
| EA201991069A1 (ru) | Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом | |
| PE20212333A1 (es) | Compuestos de acido ascorbico y quinona en combinacion con un agente antiparasitario para el tratamiento de una enfermedad parasitaria |